8-K: BioAffinity Technologies Reports Q3 2026 Results
Current Report (Form 8-K)
BioAffinity Technologies announced a 79% year-to-date increase in CyPath Lung testing revenue and doubled unit sales, alongside progress in its precision medicine pipeline.
Summary
- bioAffinity Technologies reported third quarter 2026 results, showing significant growth in CyPath Lung test unit sales (doubled year-to-date) and a 79% increase in testing revenue to approximately $1.1 million for the first nine months of 2026.
- The company expanded its physician utilization of CyPath Lung, with ordering physicians increasing by 89% in Q3 2026 compared to Q3 2025, and existing users increasing their volume by 48%.
- Progress was made in the precision medicine pipeline with new research for asthma and COPD, a collaboration with Pictor, Inc., and continued development of topical skin cancer therapeutics.
- The company raised $8.0 million in gross proceeds through offerings in August and October 2026 for working capital and general corporate purposes.
- Net loss for Q3 2026 was approximately $5.3 million, an increase from $5.1 million in Q3 2025, primarily due to an increase in loss from operations.
- Cash and cash equivalents stood at approximately $2.6 million as of September 30, 2026, with an additional $4.0 million raised subsequent to the quarter-end.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant commercial momentum for CyPath Lung and advancements in its research pipeline, despite a widening net loss.
Positives
- CyPath Lung test unit sales doubled year-to-date compared to the first nine months of 2025.
- CyPath Lung testing revenue increased 79% year-to-date to approximately $1.1 million.
- The number of ordering physicians for CyPath Lung increased by 89% in Q3 2026 compared to Q3 2025.
- Existing physicians ordering CyPath Lung tests increased their volume by 48% year over year.
- Expanded government healthcare distribution network through an agreement with Av MEDICAL.
- Advanced CyPath Lung for potential use in surveillance of lung cancer survivors.
- Published a clinical review and white paper on CyPath Lung by the Chief Medical Officer.
- Received a Notice of Allowance from the Japan Patent Office for the CyPath Lung test's method.
Negatives
- Total revenue for Q3 2026 was approximately $1.1 million, a decrease from approximately $1.4 million in Q3 2025.
- The decrease in Q3 revenue is attributed to a decrease in average reimbursement per CyPath Lung test and a slight decline in total cases completed at Precision Pathology Laboratory Services (PPLS).
- Net loss for Q3 2026 was approximately $5.3 million, an increase from approximately $5.1 million in Q3 2025.
- Operating expenses increased to approximately $4.6 million in Q3 2026 from approximately $3.7 million in Q3 2025.
- Cash and cash equivalents decreased to approximately $2.6 million as of September 30, 2026, from approximately $6.4 million at December 31, 2025.
Risks
- The Company's ability to expand the commercial adoption of CyPath Lung and capitalize on government healthcare market opportunities.
- The timing, cost, enrollment, and outcome of clinical studies.
- The possibility that preliminary, in vitro, or study-specific findings will not be replicated or translate into safe and effective therapies or commercial products for asthma, COPD, or skin cancer.
- The need for further validation of new applications, including surveillance.
- The extent and timing of physician adoption, repeat utilization, and customer retention.
- Payer coverage, reimbursement rates, and collections.
- The Company's ability to obtain, maintain, and enforce intellectual property rights.
Future Outlook
The company is focused on disciplined execution, expanding commercial adoption of CyPath Lung, and advancing its clinical and research programs. Priorities include leveraging expertise in flow cytometry, automated data analysis, and siRNA technology for differentiated products in lung disease and skin cancer markets. Further development and validation are underway for asthma and COPD diagnostics, and topical therapeutics for skin cancer.
Management Comments
- "Our third-quarter results reflect CyPath Lung's continued momentum in addressing the critical need for early lung cancer detection, driven by both new physicians ordering the test and increased use by existing customers."
- "We believe this growth reflects increasing physician engagement and recognition of the role CyPath Lung can play in managing care for patients at risk for lung cancer."
- "We are also advancing its potential use in surveillance following curative-intent treatment, where CyPath Lung could complement imaging in monitoring for recurrence and new cancers."
- "Peer-to-peer education and growing clinical experience with the test remain important drivers of adoption, while our longitudinal study is designed to generate robust, real-world data across multiple sites to further evaluate how CyPath Lung may support risk assessment and clinical decision-making."
- "We continue to build the foundation for long-term growth. Beyond lung cancer, we are advancing our platform to take advantage of precision medicine opportunities in asthma and COPD, where sputum-based analysis may help characterize lung inflammation and help physicians better match individual patients to available treatments."
- "Our patent portfolio now includes 22 awarded U.S. and foreign patents and 36 pending applications."
- "Our distribution agreement with Av MEDICAL is intended to expand our reach into government healthcare markets, including the VA, where the substantial burden of lung cancer underscores the need for more effective ways to evaluate pulmonary nodules and improve patient outcomes."
- "Our priorities remain disciplined execution, expanding commercial adoption and advancing our clinical and research programs."
Industry Context
StockSavvy.ai notes that bioAffinity Technologies is operating in the highly competitive and rapidly evolving fields of early disease detection and precision medicine. The reported growth in CyPath Lung adoption aligns with the broader industry trend towards non-invasive diagnostics and personalized treatment approaches. The company's expansion into asthma and COPD diagnostics and topical skin cancer therapeutics reflects a strategy to leverage its core platform technologies across multiple high-value healthcare markets.
Stakeholder Impact
- Shareholders: The capital raises provide necessary funding for operations and growth, but also dilute existing ownership. The increased net loss and decreased cash position may be concerns, offset by positive commercial momentum.
- Physicians: Increased utilization of CyPath Lung suggests growing acceptance and perceived value in clinical practice.
- Patients: Advancements in early lung cancer detection and potential new therapies for lung and skin cancers offer improved health outcomes.
- Government Healthcare Agencies (e.g., VA): Expansion into this market through Av MEDICAL could increase access to diagnostic tools for veterans.
- Suppliers/Partners (e.g., Pictor, Inc.): Collaboration indicates ongoing partnerships for product development.
Next Steps
- Continue to expand commercial adoption of CyPath Lung.
- Advance CyPath Lung for potential use in surveillance of lung cancer survivors.
- Further develop and validate noninvasive tests to characterize lung inflammation for asthma and COPD therapies.
- Continue research into potential topically delivered therapeutics for squamous and basal cell skin cancers.
- Expand reach into government healthcare markets, including the VA, through the Av MEDICAL agreement.
- Generate robust, real-world data from the ongoing longitudinal clinical trial.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Comparison period for Q3 2026 results (e.g., testing revenue, physician utilization). |
| 2025-12-31 | Comparison period for cash and cash equivalents. |
| 2026-07-01 | Company surpassed total CyPath Lung test reports delivered to physicians during 2025. |
| 2026-08-01 | Private placement offering completed, raising gross proceeds. |
| 2026-09-30 | End of third quarter for financial reporting; 11 clinical sites active for CyPath Lung trial. |
| 2026-10-01 | Registered direct offering and concurrent private placement completed, raising gross proceeds. |
| 2026-10-01 | Dr. Downie presented CyPath Lung framework to physicians at CHEST 2026. |
| 2026-11-06 | Date of the Form 8-K filing and press release. |
Recommendation
holdThe company shows strong commercial traction for its lead product, CyPath Lung, with significant revenue and utilization growth. However, this is balanced by an increasing net loss and a decreasing cash balance, although mitigated by recent capital raises. The company is also investing in a pipeline of future products. A 'hold' recommendation reflects the positive commercial execution and future potential, tempered by the current financial performance and the inherent risks in biotechnology development.
Keywords
CyPath Lung, lung cancer detection, biotechnology, precision medicine, asthma, COPD, skin cancer therapeutics, sputum analysis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.